Emerging Therapies in Neovascular Age-Related Macular Degeneration in 2020
| Autor: | Arshad M. Khanani, Mahima Jhingan, Jay Chhablani, Aamir A Aziz, Anindya Samanta, Sumit Randhir Singh |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Vascular Endothelial Growth Factor A
medicine.medical_specialty emerging treatments Visual acuity genetic structures Visual Acuity neovascular AMD Angiogenesis Inhibitors Review Article Neovascularization Biological Factors 03 medical and health sciences 0302 clinical medicine Ophthalmology Age related wet AMD medicine Humans business.industry General Medicine Macular degeneration medicine.disease eye diseases T014 Clinical trial Geographic atrophy Treatment Outcome medicine.anatomical_structure Intravitreal Injections Drug reservoir Wet Macular Degeneration 030221 ophthalmology & optometry sense organs Choroid medicine.symptom business 030217 neurology & neurosurgery |
| Zdroj: | Asia-Pacific Journal of Ophthalmology (Philadelphia, Pa.) |
| ISSN: | 2162-0989 |
| DOI: | 10.1097/apo.0000000000000291 |
| Popis: | Age-related macular degeneration (AMD) is one of the most common causes of vision loss. Advanced forms of AMD are seen in primarily 2 types—neovascular AMD (nAMD) with the presence of choroid neovascularization and nonneovascular AMD (nnAMD) with geographic atrophy. Although there are 4 anti-vascular endothelial growth factor drugs either widely used or approved for the former, there are no current treatments for the latter. This review will highlight upcoming treatments for AMD currently in clinical trials. For nAMD: Abicipar pegol, an intravitreal anti-vascular endothelial growth factor based on designed ankyrin repeat proteins (DARP) in protein, is currently pending approval. Conbercept and Faricimab, 2 intravitreal anti-growth factors, are currently in phase 3. Nine other upcoming agents have at least produced results in the 2A phase including intravitreal injections (KSI-301, OPT-302, RGX-314, ICON-1, and DE-122), depot (GB-102), drug reservoir (PDS), topical drops (PAN-90806), and oral formulations (AKST4290). We summarize all the newer molecules. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|